Moteur de recherche d’entreprises européennes
UK funding (2 808 683 £) : MICA : Le laboratoire de proximité de Newcastle Ukri01/09/2015 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
MICA : Le laboratoire de proximité de Newcastle
| Abstract | The introduction of new scientific methods has shown that many diseases are much more heterogeneous than originally believed and that differences between cases can have a marked influence on the way that patients respond favourably to treatment. This has led to the concept of "stratified" medicine in which treatment is adjusted to meet the needs of individual patients. This approach ensures that treatment is only given to patients who are likely to respond and has both clinical and economic benefits, as unnecessary toxicity will be avoided and expensive new therapies are conserved. The introduction of stratified medicine requires the development of diagnostic techniques which can be used in clinical practice. In order for a new test to be adopted it has to be validated using "real-life" samples and adapted so that it can be used reliably in routine clinical laboratories. For many tests this requires input from experts in Cellular Pathology. However, in recent years, due largely to service pressures, many clinical and non-clinical specialists in this discipline have been unable to dedicate time to maintaining their knowledge in Molecular Pathology or to undertake research themselves. Our bid responds to the three areas for need identified by the MRC in order to ensure that the development of new diagnostic tests keeps pace with the demands of stratified medicine; restoration of the proximity between clinical and research activity; development of a clear path between discovery science and clinical application and addressing the training needs of laboratory staff. PROXIMITY We will establish a "Proximity Laboratory" in a busy NHS service department, which is adjacent to the University Medical Faculty, involving both University and clinical staff. Three satellite laboratories will be established in the Medical School and the Transplant Institute (Freeman Hospital), to provide a well-equipped training and research environment close to the discovery laboratories. PATH Initial projects undertaken in the Proximity Laboratory will build on current expertise in treatment stratification in the fields of liver, inflammatory bowel and mitochondrial disease and childhood cancer. An advisory panel will be established to assist research teams in the development of new diagnostic approaches and 2-4 projects per year will be selected for support to generate pilot data to underpin applications for validation by funding programmes such as those operated by the NIHR or MRC. Funding by the Proximity Laboratory will generally be for 1-2 years and monitored to prevent stagnation. Links with the Newcastle Diagnostic Evaluation Co-operative (DEC) will assist with the adoption of promising new diagnostic approaches by commercial partners, thereby helping to ensure the maximum impact on clinical practice. In addition to the support given to biomedical projects the Proximity Laboratory will also promote research activity in the fields of biomedical engineering and computing science. Biomedical engineering projects will focus on the need to improve methods for handling small samples in response to a trend towards the use of minimally invasive biopsy techniques and will involve collaboration with groups based in our established nanotechnology laboratory (NanoLAB) and Diagnostic and Therapeutic Technologies Group. Collaborations will also be established with computer scientists in the Interdisciplinary Computing and Complex BioSystems (ICOS) research group in Newcastle University in order to develop new ways to present complex datasets in a way accessible for clinical application. PEOPLE Training in Molecular Pathology will be offered through a range of distance learning opportunities, up to the level of a Master's degree. In addition undergraduates will be encouraged to enter the speciality by offering bursaries for intercalated degrees. This approach will both increase capacity and help to augment the skills of existing staff |
| Category | Research Grant |
| Reference | MR/N005872/1 |
| Status | Closed |
| Funded period start | 01/09/2015 |
| Funded period end | 31/12/2019 |
| Funded value | £2 808 683,00 |
| Source | https://gtr.ukri.org/projects?ref=MR%2FN005872%2F1 |
Participating Organisations
| Newcastle University | |
| EPSRC | |
| Medical Research Council (MRC) | |
| AMLo Bioscience Ltd | |
| Bone Cancer Research Trust | |
| North Eastern Skin Research Fund | |
| Innovate UK | |
| Newcastle upon Tyne Hospitals NHS Charity | |
| Tissue Solutions UK | |
| Atelerix | |
| Leica UK Ltd | |
| University of Oxford | |
| Sir Bobby Robson Foundation | |
| RedxPharma | |
| NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST | |
| Bicycle Therapeutics | |
| Queen's University Belfast | |
| Reece Innovation Ltd | |
| Avacta Group | |
| National Cancer Research Institute (NCRI) | |
| Wellcome Trust | |
| Nascient ltd | |
| Genentech, Inc | |
| Astrazeneca | |
| LIVErNORTH | |
| Cancer Research UK | |
| Rosetrees Trust | |
| FibroFind Ltd | |
| Achilles Therapeutics Ltd | |
| Human Technopole | |
| Resolve Therapeutics, LLC | |
| Children's Cancer and Leukaemia Group (CCLG) | |
| UK NEQAS CPT | |
| Leica Biosystems | |
| Genomics England | |
| 3Helix Inc | |
| NewGene Ltd |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Newcastle University, Newcastle upon Tyne, Royaume Uni.